A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover.
D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- / Q000031:analogs & derivatives / Q000494:pharmacology*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002417:Cattle; D002837:Chromaffin Granules / Q000378:metabolism / Q000648:ultrastructure; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D003641:Deamination; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D008781:Methyltyrosines / Q000494:pharmacology; D051379:Mice; D011807:Quinolizines / Q000494:pharmacology*; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors; D013045:Species Specificity
D014150:Antipsychotic Agents; D001679:Biogenic Amines; D008781:Methyltyrosines; D011807:Quinolizines; D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; D012110:Reserpine; D001058:Apomorphine